|Assessment Status||Rapid Review Complete|
|Indication||For the treatment of adult patients with relapsing-remitting multiple sclerosis|
|Rapid review commissioned||28/10/2021|
|Rapid review completed||16/12/2021|
|Rapid review outcome||A full HTA is not recommended. The NCPE recommends that diroximel fumarate not be considered for reimbursement at the submitted price*|
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.
The HSE has approved reimbursement following confidential price negotiations July 2022.